FIELD: medicine.
SUBSTANCE: invention relates to a method for treating a Trk-related childhood cancer in a subject in need thereof, comprising administering to said subject a liquid formulation containing a therapeutically effective amount of (S) -N- (5 - ((R) -2- (2, 5-difluorophenyl) pyrrolidin-1-yl) pyrazolo [1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide of formula (I), a pharmaceutically acceptable salt thereof, or combinations thereof, hydroxypropyl-β-cyclodextrin, sodium citrate and sweetener, wherein the pH of the specified formulation is from 2.5 to 5.5, and the concentration of the specified compound of formula (I), its pharmacologically acceptable salt or their combination in the liquid formulation is from 20 to 30 mg/ml. The invention also relates to variants of a method for treating childhood cancer associated with Trk.
EFFECT: method for treating childhood cancer associated with Trk is provided, in which a liquid formulation is administered containing a therapeutically effective amount of a compound of formula (I), hydroxypropyl-β-cyclodextrin, sodium citrate and a sweetener, wherein the pH of the said formulation is from 2.5 to 5.5.
(I)
35 cl, 14 dwg, 17 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LIQUID COMPOSITIONS (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)PYRROLIDINE-1-YL)PYRAZOLO[1,5-A]PYRIMIDINE-3-YL)-3-HYDROXYPYRROLIDINE-1-ARBOXAMIDE | 2017 |
|
RU2751767C2 |
| POINT MUTATIONS IN TRK INHIBITOR-RESISTANT MALIGNANT TUMORS AND RELATED METHODS | 2016 |
|
RU2744852C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTI-IL-5 ANTIBODY, AND USE THEREOF | 2020 |
|
RU2824390C2 |
| TREATMENT OF MUSCULAR WEAKNESS WITH ALKALINE PHOSPHATASES | 2017 |
|
RU2754558C2 |
| PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION | 2019 |
|
RU2791683C2 |
| COMBINATION OF CELL THERAPY AND IMMUNOMODULATOR COMPOUND | 2018 |
|
RU2777911C2 |
| PHARMACEUTICAL COMPOSITIONS OF PEGYLATED LIPOSOMES AND COAGULATION FACTORS | 2015 |
|
RU2737291C2 |
| TREATMENT OF DISEASES BY MEANS OF EXPRESSION OF ENZYME WITH DEOXYRIBONUCLEASE (DNase) ACTIVITY IN LIVER | 2019 |
|
RU2773691C2 |
| PHARMACEUTICAL COMPOSITION AND METHOD OF PREVENTION AND TREATMENT OF LYSOSOMAL ENZYME DEFICIENCY IN SUBJECT WITH TYPE II MUCOPOLYSACCHARIDOSIS | 2023 |
|
RU2814280C1 |
| ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE | 2019 |
|
RU2795457C2 |
